Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, Tollens F, Ricke J, Rübenthaler J, Schmidt-Hegemann NS, Herlemann A, Unterrainer M, Kunz WG.
Mehrens D, et al. Among authors: rubenthaler j.
J Natl Compr Canc Netw. 2023 Jan;21(1):43-50.e2. doi: 10.6004/jnccn.2022.7070.
J Natl Compr Canc Netw. 2023.
PMID: 36634610